Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.
Sponsor: University of California, Los Angeles
You may qualify if…
- ✓ Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
- ✓ \>18 years of age and willing to participate
- ✓ Male or post-menopausal females
You may not qualify if…
- ✕ History of prior neck surgery and /or neck irradiation
- ✕ Use of beta blocker agents
- ✕ Use of any other glucose lowering medication
- ✕ History of neuropathic disorders (e.g. diabetic neuropathy)
- ✕ Diabetic patients
- ✕ Individuals without normal thyroid function
- ✕ Individuals with cancer
- ✕ Any significant chronic disease or renal, hepatic or endocrine disease
Where it's recruiting
Los Angeles
Source: ClinicalTrials.gov · NCT05419726 · last updated 2025-05-11